In this article, we will look at the 10 Best Performing American Stocks in June 2026.
June’s biggest American stock winners came during a market where investors were highly rewarding companies tied to earnings growth, AI infrastructure, cyclicals, and sector-specific catalysts.
Fidelity says “Market breadth has broadly remained strong” and “unrelenting corporate earnings growth has underpinned stocks.” That suggests some recent rallies are happening in a market still supported by profits, not just sentiment. BlackRock adds that “U.S. company earnings offered a big surprise to the upside” and that “Earnings strength is broadening,” which helps explain why investors have been willing to move beyond the usual mega-cap leaders. Capital Group also notes that markets are broadening into a “broadening opportunity set,” while stressing “active stock selection, supported by deep research.”
Against this backdrop, some of June’s best-performing American stocks may signal changing earnings expectations, renewed sector leadership, or company-specific momentum. With that in mind, let’s take a look at the 10 Best Performing American Stocks in June 2026.
Pixabay/Public Domain
Our Methodology
We used the Finviz screener to identify American stocks that rallied by at least 30% in the month of June. We then limited our final selection to companies that have recently reported noteworthy developments likely to impact investor sentiment. These stocks are also popular among analysts and elite hedge funds.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Insider Monkey’s quarterly newsletter strategy selects 14 small-cap and large-cap stocks every quarter and has returned 599.2% since May 2014, beating its benchmark by 372 percentage points (see more details here).
10. Moderna, Inc. (NASDAQ:MRNA)
On July 7, 2026, RBC Capital raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $45 from $38 and kept a Sector Perform rating on the shares as part of a broader Q2 earnings preview for biotech. RBC said the biotech sector has gained considerable momentum, helped by strong data expanding innovative spaces and perceptions of improving FDA flexibility and stability. The firm added that Q2 earnings are shaping up to be seasonally strong, with multiple opportunities for beats and continued M&A activity.
On June 26, Piper Sandler raised the firm’s price target on Moderna, Inc. (NASDAQ:MRNA) to $77 from $69 previously and kept an Overweight rating on the shares.
On June 25, Moderna announced research and early development updates at its Science Day event. The company said it is balancing near-term growth with long-term innovation, supported by its four approved products, infectious disease launches, geographic expansion, and late-stage pipeline opportunities, including investigational intismeran autogene therapy and propionic acidemia therapeutic. Moderna also said its Scientific Intelligence Engine uses data, AI, and machine learning, automation, and robotics to accelerate discovery and improve operations.
Moderna, Inc. (NASDAQ:MRNA) provides messenger RNA medicines in the United States, Europe, and internationally.
9. Butterfly Network, Inc. (NYSE:BFLY)
On July 2, 2026, Butterfly Network, Inc. (NYSE:BFLY) announced the commercial availability of its Butterfly iQ+ and iQ3 handheld ultrasound devices and mobile application in Brazil through authorized distribution partners. John Soto, Senior Vice President of International at Butterfly Network, said meeting Brazil’s regulatory and certification requirements reflects the strength of Butterfly’s technology and its ability to bring ultrasound solutions to clinicians in markets with high standards.
On June 18, Butterfly Network provided commentary following Midjourney’s public announcement of Midjourney Medical and The Midjourney Scanner, a full-body tomographic imaging machine. The current scanner prototype incorporates 40 Butterfly Ultrasound-on-Chip imaging modules per system under a co-development agreement between the two companies. Future generations are expected to use substantially more imaging modules as the platform evolves and scales.
CEO Joseph DeVivo said Midjourney’s whole-body scanner has “no radiation, no magnetic risk, low cost, and accessible,” with about half a million sensors scanning simultaneously and over two petaflops of processing power. DeVivo said Butterfly is supporting Midjourney’s mission to democratize access to personal imaging data, and that the roadmap introduced by Founder David Holz represents a potentially meaningful commercial opportunity for Butterfly.
Butterfly Network, Inc. (NYSE:BFLY) develops, manufactures, and commercializes ultrasound imaging solutions in the United States and internationally.
8. Biohaven Ltd. (NYSE:BHVN)
On June 30, 2026, Biohaven Ltd. (NYSE:BHVN) announced the completion of enrollment in RISE3, a pivotal Phase 2/3 randomized, double-blind, placebo-controlled study evaluating opakalim for refractory focal epilepsy. Opakalim is Biohaven’s selective Kv7.2/7.3 channel activator, and top-line results from the study are expected in 2H 2026.
On June 29, Biohaven announced enrollment of the first patient in the pivotal Phase 3 trial of BHV-1300 for Graves’ disease. BHV-1300 is the first MoDE extracellular protein degrader, described by the company as a novel small molecule IgG1, 2, and 4 degrader that uses the body’s clearance machinery to eliminate the IgG1 TSHR autoantibody driving Graves’ disease.
On June 26, Deutsche Bank raised the firm’s price target on Biohaven to $20 from $15 and kept a Buy rating on the shares. Deutsche Bank said the company’s troriluzole in spinocerebellar ataxia could be the next beneficiary of recent FDA reversals.
Biohaven Ltd. (NYSE:BHVN) focuses on the discovery, development, and commercialization of treatments for immunology, neuroscience, and oncology therapeutic areas worldwide.
7. Sezzle Inc. (NASDAQ:SEZL)
On June 29, 2026, Oppenheimer downgraded Sezzle Inc. (NASDAQ:SEZL) to Perform from Outperform, “solely on valuation,” after a 158% year-to-date rise in the shares. Oppenheimer said it still expects Sezzle to remain one of the fastest gross profit and adjusted EBITDA growers in its coverage, supported by market share gains, Buy Now Pay Later industry expansion, and product innovation. The firm sees room for Sezzle to again raise full year EPS guidance from $5.10, but said the recent share-price strength suggests investors are already pricing in potential 2026 EBITDA outperformance.
On June 25, Northland analyst Mike Grondahl raised the firm’s price target on Sezzle to $170 from $160 and kept an Outperform rating on the shares. After meeting with management during Northland’s Growth Conference, Grondahl said he got more insight into the company’s marketing strategy and ramp, engagement with Pay in 5 and SezzleCash, and bank charter progress.
Earlier in June, B. Riley raised the firm’s price target on Sezzle to $141 from $117 and kept a Buy rating on the shares. B. Riley said Sezzle integrated with Knot’s CardSwitcher API to automatically update Sezzle virtual cards as the preferred payment method across merchants, including Amazon (AMZN), Walmart (WMT), and Uber (UBER). The firm said the integration should improve checkout convenience and help drive top-of-wallet behavior among users.
Sezzle Inc. (NASDAQ:SEZL) operates as a technology-enabled payments company in the United States and Canada.
6. Kymera Therapeutics, Inc. (NASDAQ:KYMR)
On June 30, 2026, BofA raised the firm’s price target on Kymera Therapeutics, Inc. (NASDAQ:KYMR) to $125 from $110 and kept a Buy rating on the shares. BofA adjusted its launch timing expectations after Kymera said enrollment in the phase 2b BROADEN trial evaluating KT-621 in atopic dermatitis was completed approximately 6 months ahead of schedule. BofA currently models $6B in nominal peak sales for KT-621 in AD.
On June 29, B. Riley raised the firm’s price target on Kymera Therapeutics to $155 from $117 and kept a Buy rating on the shares. B. Riley said the company unexpectedly completed BROADEN2 Phase 2b enrollment in moderate-to-severe atopic dermatitis six months early. The firm noted that Kymera moved the readout to year-end 2026 from mid-2027 and is advancing the planned Phase 3 initiation to mid-2027. B. Riley said it is a buyer of the stock on the “encouraging update,” calling KT-621 Kymera’s “single most important value driver.”
Also on June 29, Truist analyst Srikripa Devarakonda raised the firm’s price target on Kymera Therapeutics to $136 from $116 and kept a Buy rating on the shares. Devarakonda viewed Kymera positively following accelerated development timelines for KT-621, with clinician feedback pointing to strong interest in an oral therapy with Dupixent-like efficacy and high enthusiasm among dermatology key opinion leaders.
Kymera Therapeutics, Inc. (NASDAQ:KYMR) focuses on discovering and developing small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.
While we acknowledge the potential of KYMR to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than KYMR and that has 100x upside potential, check out our report about the cheapest AI stock.
5. TG Therapeutics, Inc. (NASDAQ:TGTX)
On July 6, 2026, TG Therapeutics, Inc. (NASDAQ:TGTX) announced the initiation of a Phase 2 clinical trial evaluating Briumvi in adults with treatment-resistant schizophrenia. The open-label study is designed to evaluate the efficacy and safety of Briumvi in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite standard-of-care antipsychotic treatment.
On June 23, Jefferies raised the firm’s price target on TG Therapeutics to $83 from $57 and kept a Buy rating on the shares. Jefferies said the Street “still underappreciates the significance” of Phase 1 subcutaneous Briumvi pharmacokinetic data as predictive of a Phase 3 outcome expected by year-end 2026 to early 2027. Jefferies also updated its model to be more bullish on the subcutaneous opportunity.
On June 9, TG Therapeutics announced topline Phase 1 data for Briumvi in patients with myasthenia gravis and the initiation of a Phase 2 trial evaluating Briumvi as maintenance therapy after induction with efgartigimod. At Week 24, 82% of patients achieved the Minimal Clinically Important Difference in MG-ADL, with a median time to MCID of 30 days, while mean MG-ADL improvement was 4.6 points. The Phase 2 trial is expected to enroll approximately 120 patients, with time to clinical worsening as the primary endpoint.
TG Therapeutics, Inc. (NASDAQ:TGTX) focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally.
4. CoreCivic, Inc. (NYSE:CXW)
On July 7, 2026, Benchmark raised the firm’s price target on CoreCivic, Inc. (NYSE:CXW) to $41 from $36 and kept a Buy rating on the shares. Benchmark cited CoreCivic’s sale of two California facilities to the U.S. Department of Homeland Security for $1.5B in gross proceeds. The firm said the company is using initial proceeds to eliminate debt and enable share repurchases, while remaining positioned to benefit from potential additional facility sales as DHS continues expanding detention capacity.
On July 6, CoreCivic announced that it completed the sale of its 2,560-bed California City Detention Facility in California City, California, and its 1,994-bed Otay Mesa Detention Center in San Diego, California, to the United States of America and its assigns, through the Department of Homeland Security, for an aggregate gross sales price of $1.5B. CEO Patrick Swindle said the sales demonstrate the value of CoreCivic’s real estate portfolio and provide “significant balance sheet flexibility.”
On June 26, Northland raised the firm’s price target on CoreCivic to $40 from $32 and kept an Outperform rating on the shares. Northland said meetings with security services companies increased its comfort and confidence that the back half of 2026 is positioned to be active. The firm also said timing around the government’s current initiative to acquire private detention facilities remains on track with previous expectations.
CoreCivic, Inc. (NYSE:CXW) owns and operates partnership correctional, detention, and residential reentry facilities in the United States.
3. Dave Inc. (NASDAQ:DAVE)
On July 1, 2026, Benchmark analyst Mark Palmer raised the firm’s price target on Dave Inc. (NASDAQ:DAVE) to $475 from $345 and kept a Buy rating on the shares. Palmer noted that Dave’s share price is up more than 68% year-to-date and said the reasons the stock has decoupled from a fintech group “that the market has spent much of the year selling” are “precisely the reasons” Benchmark believes the stock could have another leg up. Palmer added that the Flex Pay-in-4 card, expected to debut in 2027, should sustain Dave’s momentum.
On June 12, Barrington raised the firm’s price target on Dave to $310 from $290 and kept an Outperform rating on the shares after meeting with management. Barrington said the company’s outlook “remains very positive,” citing Dave’s strategy of acquiring new members, increasing engagement through ExtraCash, and deepening customer relationships with the Dave Card. The firm also said Dave’s large addressable market offers growth opportunities.
On June 10, Dave announced that, effective June 1, 2026, it began transitioning ExtraCash receivables to its strategic funding arrangement with Coastal Community Bank, the wholly owned banking subsidiary of Coastal Financial Corporation (CCB). The arrangement is expected to reduce Dave’s direct funding obligations, lower its cost of capital, and unlock over $200M of liquidity on Dave’s balance sheet once originations are transitioned to Coastal. CEO Jason Wilk called the milestone a “meaningful unlock,” pointing to lower cost of capital, reduced balance sheet exposure, and added liquidity for capital allocation priorities.
Dave Inc. (NASDAQ:DAVE) provides various financial products and services through its financial services platform in the United States.
2. Twist Bioscience Corporation (NASDAQ:TWST)
On July 6, 2026, Evercore ISI downgraded Twist Bioscience Corporation (NASDAQ:TWST) to In Line from Outperform with a price target of $102, up from $66. Evercore ISI said Twist has been one of the best performers in life science tools, up more than 200% year-to-date, with most of the move, or 85%, coming since its May 21 analyst day on optimism around AI-driven order momentum. The firm said it is taking some profits after the rally.
On June 29, Guggenheim raised the firm’s price target on Twist Bioscience to $107 from $60 and kept a Buy rating on the shares. Guggenheim adjusted models and forecasts for select companies in its diagnostics and life sciences tools coverage after meetings with management teams.
On June 24, Barclays analyst Luke Sergott raised the firm’s price target on Twist Bioscience to $95 from $65 and kept an Overweight rating on the shares. Sergott adjusted targets in the life science and diagnostic tools space as part of a Q2 preview, noting that tools are “gaining favor among healthcare subsectors.” Barclays expects in-line to modest beats in Q2 for the group.
Twist Bioscience Corporation (NASDAQ:TWST) manufactures and sells synthetic DNA-based products.
1. SELLAS Life Sciences Group, Inc. (NASDAQ:SLS)
On July 6, 2026, Alliance Global analyst James Molloy raised the firm’s price target on SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) to $25 from $10 and kept a Buy rating on the shares. Molloy said the firm is awaiting the final two deaths in the ongoing Galinpepimut-S Phase 3 REGAL trial in acute myeloid leukemia patients achieving second complete remission. Alliance Global views the delay in top-line data as a potentially significant positive, since it suggests patients may be living longer than anticipated on Best Available Therapy in the CR2 AML setting.
In May, SELLAS reported financial results for the first quarter ended March 31, 2026, and provided a corporate update. CEO Angelos Stergiou said the first quarter marked an “important period” as SELLAS continued executing across clinical programs while preparing for the anticipated pivotal Phase 3 REGAL trial data readout. Stergiou said the upcoming results, triggered by the pre-specified 80th event, will be an “important milestone” for the company. SELLAS said that as of May 11, 2026, 78 events had occurred in the Phase 3 REGAL trial, with the 80th event set to trigger database lock, blinded data review procedures, statistical analysis, unblinding, and disclosure of topline results. The company also initiated an 80-patient Phase 2 trial of SLS009 in newly diagnosed AML patients, with topline data expected in Q4 2026. SELLAS also established an ATM equity offering under its S-3ASR shelf registration, allowing it to raise up to $150 million over time, and said it has not sold any shares through the ATM to date.
SELLAS Life Sciences Group, Inc. (NASDAQ:SLS) focuses on the development of novel therapeutics for various cancer indications in the United States.
While we acknowledge the potential of SLS to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than SLS and that has 100x upside potential, check out our report about the cheapest AI stock.
READ NEXT: 10 Fastest Growing Asian Stocks to Buy Now and 12 High Quality Stocks to Buy for the Long Term.
Disclosure: None. Follow Insider Monkey on Google News.
